Outcomes11

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 11 of 11

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Absolute Breast Density	2 years	The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.	cm squared	MEAN
SECONDARY	Changes in Biomarkers for Oxidative Stress:Urinary 8-(Isoprostane) F-2α	1 year	Biomarker measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 47).	pg/mg creatinine	MEAN
SECONDARY	Changes in Biomarkers for Oxidative Stress: Urinary 8-hydroxy-deoxyguansine	1 year	Biomarker measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 47).	ng/mg creatinine	MEAN
SECONDARY	Changes in Biomarkers for Estrogen Metabolism: 2-hydroxy Estrone (Urinary 2-OHE1) and 16-α-hydroxy Estrone (16α-OHE1)	1 year	Biomarker measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 47).	ng/mg creatinine	MEAN
SECONDARY	Changes in Serum Biomarkers for Inflammation From Levels of High Sensitivity C-reactive Protein (hsCRP) and Interleukin 6 (IL-6)	1 Year	Biomarker measurements were not taken for the entire population of the study (N = 266) due to non-significant trends for treatment effects found in this initial population (n = 89).	pg/ml	MEAN
SECONDARY	Changes in Insulin-like Growth Factor-1 (IGF-1) and Insulin-like Growth Factor-1 Binding Protein-3 (IGFBP-3)	1 year	Measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 46).	ng/mL	MEAN
SECONDARY	Changes in Serum Lipid Levels	2 years	The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.	mg/dL	MEAN
SECONDARY	Changes in Complete Blood Count: Red Blood Cells	2 years	The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.	millions of cells per microliter	MEAN
SECONDARY	Changes in Complete Blood Count: Hemoglobin	2 years	The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.	g/dL	MEAN
SECONDARY	Changes in Complete Blood Count: Hematocrit	2 years	The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.	volume percentage	MEAN
SECONDARY	Changes in Complete Blood Count: White Blood Cells and Platelets	2 years	The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.	thousand cells/mL	MEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00723398/outcomes

API reference For AI assistants